New drug combo after brain radiation shows promise for lymphoma patients

NCT ID NCT06607549

Recruiting now Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times

Summary

This early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot receive standard high-dose chemotherapy. The goal is to find the best dose and see if the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: loncastuximab tesirine and rituximab (Lonca-R) given intravenously after stereotactic radiosurgery
What this could lead to: If successful, this could offer a new treatment option for patients with central nervous system lymphoma who have relapsed or cannot tolerate standard chemotherapy.
What could go wrong: This is a very early phase 1 trial with only 12 participants, focused on safety and dosing. It is too small to prove effectiveness, and the combination may cause side effects or fail to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma of the central nervous system primary central nervous system lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Brown University Health Rhode Island Hospital
RECRUITING

Providence, Rhode Island, 02903, United States
Huntsman Cancer Institute at University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
Sidney Kimmel Comprehensive Cancer Center at Jefferson
RECRUITING

Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.